Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ascierto, Paolo A.; Del Vecchio, Michele; Robert, Caroline; Mackiewicz, Andrzej; Chiarion-Sileni, Vanna; Arance, Ana; Lebbe, Celeste; Bastholt, Lars; Hamid, Omid; Rutkowski, Piotr; McNeil, Catriona; Garbe, Claus; Loquai, Carmen; Dreno, Brigitte; Thomas, Luc; Grob, Jean-Jacques; Liszkay, Gabriella; Nyakas, Marta; Gutzmer, Ralf; Pikiel, Joanna; Grange, Florent; Hoeller, Christoph; Ferraresi, Virginia; Smylie, Michael; Schadendorf, Dirk; Mortier, Laurent; Svane, Inge Marie; Hennicken, Delphine; Qureshi, Anila; Maio, Michele

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Autor(en):

Ascierto, Paolo A.; Del Vecchio, Michele; Robert, Caroline; Mackiewicz, Andrzej; Chiarion-Sileni, Vanna; Arance, Ana; Lebbe, Celeste; Bastholt, Lars; Hamid, Omid; Rutkowski, Piotr; McNeil, Catriona; Garbe, Claus; Loquai, Carmen; Dreno, Brigitte; Thomas, Luc; Grob, Jean-Jacques; Liszkay, Gabriella; Nyakas, Marta; Gutzmer, Ralf; Pikiel, Joanna; Grange, Florent; Hoeller, Christoph; Ferraresi, Virginia; Smylie, Michael; Schadendorf, Dirk; Mortier, Laurent; Svane, Inge Marie; Hennicken, Delphine; Qureshi, Anila; Maio, Michele

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Lancet Oncology (2017), Bd. 18, H. 5, S. 611-622

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(17)30231-0

ISSN:

1474-5488